In sharp contrast to the branded pharmaceutical market, which has stalled in recent year, the generics market is enjoying a period of unprecedented success. In 2005 the world generics market was worth $45bn, a growth of 14% on the previous year. Visiongain expects this level of growth to continue over the forecast period of this report.

The loss of patent protection by 2009 of almost $80bn worth of top selling drugs will be the major driving force for this generic market growth. Additionally, as healthcare costs in the developed world continue to increase, and the growth of pharmaceutical markets in developing countries continues to grow. More generic copies of successful drugs are being sold worldwide than ever before. This report describes how this burgeoning market will change over the forecast period and highlights the important issues for both originator companies and generic drugs manufacturers.

What is the therapeutic area with the most potential for generic companies? How are branded pharmaceutical companies preparing for the increasing threat of generic penetration? What challenges do generic companies face in the coming years? Read visiongain's The World Generics Market 2006-2011 report to find out.

The following issues are covered in detail:

? A summary of the relevant legislation affecting the generics industry ? A market forecast for the world generics market 2006-2011 ? An assessment of the drivers and restraints of the market during this period ? A discussion of the attitudes to generics in different regions including the US, Europe and Asia ? The issue of Biogenerics and the changes in regulations required for their success ? A review of strategies for success for originator and generics companies

Why should you buy this report?

The progress of the generic pharmaceutical market is of great importance to anyone in the pharmaceutical industry. This report provides detailed financial data and invaluable opinion about how this market will change over the important period to come.

Companies Mentioned in this report:

Abbott

Actavis

Alpharma

Amgem

Andrx

Apotex

Astellas

AstraZeneca

Azko Nobel

Barr

Biogen Idec

Bristol-Myers-Squibb

Cipla

Dr Reddy?s

Eli Lilly

Forest Laboratories

Genentech

Genzyme Transgenics

GlaxoSmithKline

GTC Biotherapeutics

IVAX

Johnson and Johnson

Lunbeck A/S

Merck

Mylan Laboratories

Nicholas Piramal

Novartis

Pentech

Pfizer

Pliva

Rambaxy

Roche

Sandoz

Sanofi-Aventis

Schering-Plough

Schwarz Pharma

Sicor

Synthon Pharmaceuticals

Teva

TranXenoGen

Viragen

Watson Pharmaceuticals

Wyeth